en · de · es · pt
melanotan-2-notes.peptides7501.com › Blog › Chemistry And Receptor Pharmacology — Practical Notes

Chemistry And Receptor Pharmacology — Practical Notes

By Editorial Desk · published 2026-05-26 · last reviewed 2026-07-01 · Blog

A practical reference on melanocortin receptors: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.

Reviewed 2026-07-01. Anything still debated is marked as such rather than presented as settled.

Chemistry and Receptor Pharmacology

Published pharmacokinetic information is limited and comes mainly from small studies rather than registrational trials. Plasma half-life is usually described as short, on the order of tens of minutes, followed by rapid tissue distribution and clearance of the intact peptide. Metabolites and low concentrations of parent compound have been reported in urine, a detail relevant to anti-doping and forensic testing. Whether repeated exposure changes receptor sensitivity or clearance over time remains an open question. Values differ noticeably between analytical assays, so published numbers should be read as approximate rather than definitive.

Melanotan II is a synthetic cyclic heptapeptide with the sequence Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, corresponding to a molecular formula of C50H69N15O9 and a monoisotopic mass near 1024 daltons. It was designed as a structural analogue of alpha-melanocyte-stimulating hormone, a peptide hormone produced by cleavage of proopiomelanocortin. A lactam bridge between the aspartate and lysine side chains closes the ring, and the C-terminal amide removes a free carboxyl group. Both modifications increase resistance to enzymatic degradation compared with the linear parent hormone. Four substitutions distinguish it from afamelanotide, the linear analogue studied under the name melanotan I.

Melanotan-2 Identity and Receptor Pharmacology

Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.

Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.

Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.

Melanotan-2 at a glance

PropertyValueNotes
Molecular formulaC50H69N15O9Cyclic heptapeptide, C-terminally amidated
Approximate molecular mass1024 DaMonoisotopic mass of the free peptide
AppearanceWhite to off-white powderTypically supplied as a lyophilised solid
Solubility classSoluble in water and polar solventsAlso dissolves in neutral aqueous buffer
Common synonymsMelanotan II, MT-II, MT-2Described as a melanocortin agonist in early literature

Reference notes

AAV is of particular interest to gene therapists due to its apparent limited capacity to induce immune responses in humans, a factor which should positively influence vector transduction efficiency while reducing the risk of any immune-associated pathology. AAV is not considered to have any known role in disease. However, host immune system response and immune tolerance reduce the efficacy of AAV-mediated gene therapy. Host immune response has been shown to respond to the AAV vectors, the transduced cells, and the transduced proteins. The immune response can be subdivided into two categories: innate and adaptive, the latter of which is divided into humoral and cell-mediated.

BioLegend was founded by CEO, Gene Lay, D.V.M., who was also the co-founder of PharMingen. In 2011, BioLegend co-developed and introduced Brilliant Violet(TM)-conjugated antibodies, using a novel fluorophore based on Nobel Prize-winning chemistry developed by Sirigen. In 2018, BioLegend introduced TotalSeq™ antibody-oligonucleotide conjugates for use in single cell proteogenomics analysis. BioLegend continued expansion and moved into a new 8-acre campus at BioLegend Way in 2019 with state of the art facilities designed to accommodate up to 1000 employees.

=== 2009 Tongchuan, Shaanxi, China === In 2009, a Chinese cement company in Tongchuan, Shaanxi Province was demolishing an old, unused cement plant and did not follow standards for handling radioactive materials. This caused some caesium-137 from a measuring instrument to be included with eight truckloads of scrap metal on its way to a steel mill, where the radioactive caesium was melted down into the steel.‍

At least several thousand years ago, some humans developed a mutation in the MCM6 gene that keeps the LCT gene turned on even after breast feeding is stopped. Populations that are lactose intolerant lack this mutation. The LCT and MCM6 genes are both located on the long arm (q) of chromosome 2 in region 21. The locus can be expressed as 2q21. The lactase deficiency also could be linked to certain heritages and varies widely. A 2016 study of over 60,000 participants from 89 countries found regional prevalence of lactose malabsorption was "64% (54–74) in Asia (except Middle East), 47% (33–61) in eastern Europe, Russia, and former Soviet Republics, 38% (CI 18–57) in Latin America, 70% (57–83) in the Middle East, 66% (45–88) in northern Africa, 42% (13–71) in northern America, 45% (19–71) in Oceania, 63% (54–72) in sub-Saharan Africa, and 28% (19–37) in northern, southern and western Europe." According to Johns Hopkins Medicine, in the United States lactose intolerance is more common in Asian Americans, African Americans, Mexican Americans, and Native Americans. Analysis of the DNA of 94 ancient skeletons in Europe and Russia concluded that the mutation for lactose tolerance appeared about 4,300 years ago and spread throughout the European population. Some human populations have developed lactase persistence, in which lactase production continues into adulthood probably as a response to the benefits of being able to digest milk from farm animals.

=== Mixed fortunes in the 21st century === The team were relegated to the Second Division in 2002; administration threatened the existence of the club as Barnsley suffered greatly due to the ITV Digital crisis. A late purchase by Barnsley's then mayor, Peter Doyle, saved the club from folding. In 2006, the side won in the play-off final at the Millennium Stadium in Cardiff, where they beat Swansea City 4–3 on penalties to earn promotion to the Championship. The manager at this time was Andy Ritchie, who was in his first season in charge after replacing Paul Hart. The team struggled in their first season back in the Championship. In November 2006, with Barnsley in the relegation zone, Ritchie was sacked in favour of Simon Davey, who managed to steer the team away from relegation in the second half of the season, and they eventually finished 20th. The following season, Barnsley reached the semi-final of the FA Cup, beating Premier League side Liverpool 2–1 at Anfield and defending champions Chelsea 1–0; the team lost 1–0 against fellow Championship side Cardiff City at Wembley in the semi-final. In October 2008, the club fielded the youngest player in the Football League's history when Reuben Noble-Lazarus came on against Ipswich Town aged 15 years and 45 days. Barnsley ended the 2011–12 season as one of only two football clubs to turn a profit in the Championship; they stayed up only because Portsmouth were given a 10-point deduction for going into administration. In 2016, Barnsley won the Football League Trophy after a 3–2 win against Oxford United.

Sources: en.wikipedia.org

Related pages on this site

Notes from published material

Under specific conditions and in the presence of other chemicals benzoic acid (a preservative) and ascorbic acid (Vitamin C) may interact to produce benzene. In March 2006, the official Food Standards Agency in United Kingdom conducted a survey of 150 brands of soft drinks. It found that four contained benzene levels above World Health Organization limits. The affected batches were removed from sale. Similar problems were reported by the US Food & Drug Administration.

The Shine–Dalgarno (SD) sequence is, sometimes partially, part of a ribosomal binding site in bacterial and archaeal messenger RNA. It is generally located around 8 bases upstream of the start codon AUG. The RNA sequence helps recruit the ribosome to the messenger RNA (mRNA) to initiate protein synthesis by aligning the ribosome with the start codon. Once recruited, tRNA may add amino acids in sequence as dictated by the codons, moving downstream from the translational start site. The Shine–Dalgarno sequence is common in bacteria, but rarer in archaea. It is also present in some chloroplast and mitochondrial transcripts. The six-base consensus sequence is AGGAGG; in Escherichia coli, for example, the sequence is AGGAGGU, while the shorter GAGG dominates in E. coli virus T4 early genes. The Shine–Dalgarno sequence was proposed by Australian scientists John Shine and Lynn Dalgarno in 1973.

On January 16, 2013, Nigel Travis, Dunkin' Brands CEO, announced that the Dunkin' Donuts franchises would be available for the first time in California beginning in 2015 although in reality, this was a return to California, as the company had several stores operating in the state up until 2002. In July 2013, Dunkin' Donuts announced that it signed its first Southern California multi-unit store development agreements with four franchise groups for a total commitment of 45 new restaurants. The first standalone restaurants were expected to open in 2015 in Orange and Los Angeles counties. The chain also planned to expand into more stores in Texas by 2015.

The Kew Fungarium accessions thousands of fungal specimens each year and operates specimen loans and visitor access comparable to a research library for fungal material. Fungaria more generally may provide on-site access and specimen loans for researchers, and their holdings are sometimes used for teaching and exhibitions. Destructive sampling is permitted within limits at Kew to support molecular work, including projects aimed at extracting genomic data from preserved fungi. Even relatively small fungaria may contain substantial undocumented diversity; in a study of the roughly 14,000-specimen Larry F. Grand Mycological Herbarium, molecular re-examination of powdery mildew specimens led to widespread redeterminations and the recognition of four previously undescribed species.

Sources: en.wikipedia.org

Background from the literature

=== Bispecific antibodies and radiolabelled haptens === The beginning of the pretargeting concept was based on bispecific antibodies which were able to bind a specific target antigen and a radiolabelled hapten. Possible was this approach because of the development of monoclonal Antibodies which could be connected to radiometal chelates. Also connecting two haptens via a two amino acid linker resulted in an enhancement effect of the affinity, which improved the uptake and retention of the radiolabelled compound without affecting the rapid clearance. Limiting factor of this approach were the slow binding constant which was rarely higher than 10−10 M, amongst other reasons.

=== In animals === In dogs, sheep, horses, and cattle, the half-life is very short: only 1– 6 minutes. Complete elimination of the drug can take up to 23 minutes in sheep and up to 49 minutes in horses. In young rats the half-life is one hour. Xylazine has a large volume of distribution of Vd = 1.9 –2.5 for horses, cattle, sheep, and dogs. Though the peak plasma concentrations are reached in 12 –14 minutes in all species, the bioavailability varies between species. The half-life depends on the age of the animal, as age is related to prolonged duration of anesthesia and recovery time. Toxicity occurs with repeated administration, given that the metabolic clearance of the drug is usually calculated as 7– 9 times the half-life, which is 4 to 5 days for the clearance of xylazine.

Richard Stephen Baldock. For services to the community in Over Wallop, Hampshire. Frank Keith Ball. Poppy Appeal Collector, Royal British Legion. For voluntary service to Veterans. Michael Lawrence Ballinger. For services to the community in Wickford and District, Essex. Sean Balmer. Coach, Cockermouth Swimming Club. For services to Swimming in Cumbria. Ian John Barnaby. Crew and Navigator, Torbay Lifeboat Station, Royal National Lifeboat Institution. For voluntary services to Maritime Safety. Robert Smart Barnes. Pipe Major, Methil and District Pipe Band. For services to Young People and to the community in Levenmouth, Fife. Wendy Angharad Barnett. Guide Leader. For services to Girlguiding and to the community in Milford Haven, Pembrokeshire. Elaine Phyllis Paterson Barnwell. Fundraiser, Royal Marines Association - The Royal Marines Charity. For Charitable Services. Dr. Michael Bartlett. Medical Educator, Hywel Dda Health Board and the Royal National Lifeboat Institution. For services to Medical Education. Kirstie Louise Baughan. Social Worker, Central Bedfordshire Council. For services to Social Work. Martin James Bazeley. For services to the community in Southwick, Hampshire. Valerie Beattie. For services to the community in County Antrim. Christine Ann Beech. Guide Leader, 1st Long Lawford Brownies, Warwickshire. For services to Young People. Andrew Colin Beevers. For services to Bell Ringing and to the community in Ecclesfield, South Yorkshire. Sheila May Betts. Chair and Volunteer, The Jarman Centre, Girlguiding Cambridgeshire East. For services to Young People.

Other uses include determining high-precision values for plutonium and uranium isotopes in a rapid fashion, investigating the atomic properties of technetium at the ultra trace level, and capturing the concurrent excitation of stable daughter atoms with the decay of their parent atoms as is the case for alpha particles, beta rays, and positrons. RIS is now in very common use in research facilities where the quick and quantitative determination of the elemental composition of materials is important. Pulsed laser light sources provide higher photon fluxes than continuous-wave lasers do, however the use of pulsed lasers currently limit vast applications of RIMS in two ways. One, photo ions are created only during short laser pulses, thus significantly reducing the duty cycle of pulsed resonance ionization mass spectrometers relative to their continuous-beam counterparts. Two, incessant drifts in laser pointing and pulse timing alongside jitters between pulses severely hamper chances of reproducibility. These issues affect the extent to which resonance ionization can be used to solve some of the challenges confronted by practical analysts today; even so, applications of RIMS are replete in various traditional and emerging disciplines such as cosmochemistry, medical research, environmental chemistry, geophysical sciences, nuclear physics, genome sequencing, and semiconductors.

Eplerenone is a newer drug that was developed as a spironolactone analog with reduced adverse effects. In addition to the y-lactone ring and the substituent on C-7, eplerenone has a 9α,11α-epoxy group. This group is believed to be the reason why eplerenone has a 20-40-fold lower affinity for the mineralocorticoid receptor than spironolactone. Despite the nonsteroidal nature of finerenone which yields a different lipophilicity and polarity profile for this compound, finerenone's affinity toward mineralocorticoid receptors is equal to that of spironolactone and 500 times that of eplerenone, hinting that the steroidal core component of most antimineralocorticoids is not essential for mineralocorticoid receptor affinity.

Sources: en.wikipedia.org

Frequently asked questions

Is melanotan II identical to alpha-melanocyte-stimulating hormone?

No. It is a synthetic analogue carrying four amino acid changes, a lactam ring and an amidated C-terminus. The natural hormone is a linear thirteen-amino-acid peptide processed from proopiomelanocortin.

How does melanotan II differ from afamelanotide?

Afamelanotide is the linear analogue [Nle4-D-Phe7]-alpha-MSH, sometimes called melanotan I, while melanotan II is cyclic and carries three further substitutions. The two are distinct molecules and are not interchangeable in analytical testing.

Is the receptor binding profile well established?

Binding to the four melanocortin receptor subtypes is well documented in vitro. The relative contribution of each subtype to whole-body effects in humans is far less certain.

What is melanotan-2 chemically?

It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.

Network